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Abstract
Background: Abnormal regulation of the inflammatory response is an important component of diseases such as diabetes,
Alzheimer’s disease and multiple sclerosis (MS). Lipoic acid (LA) has been shown to have antioxidant and anti-inflammatory
properties and is being pursued as a therapy for these diseases. We first reported that LA stimulates cAMP production via
activation of G-protein coupled receptors and adenylyl cyclases. LA also suppressed NK cell activation and cytotoxicity. In
this study we present evidence supporting the hypothesis that the anti-inflammatory properties of LA are mediated by the
cAMP/PKA signaling cascade. Additionally, we show that LA oral administration elevates cAMP levels in MS subjects.
Methodology/Principal Findings: We determined the effects of LA on IL-6, IL-17 and IL-10 secretion using ELISAs.
Treatment with 50 mg/ml and 100 mg/ml LA significantly reduced IL-6 levels by 19 and 34%, respectively, in T cell enriched
PBMCs. IL-17 levels were also reduced by 35 and 50%, respectively. Though not significant, LA appeared to have a biphasic
effect on IL-10 production. Thymidine incorporation studies showed LA inhibited T cell proliferation by 90%. T-cell activation
was reduced by 50% as measured by IL-2 secretion. Western blot analysis showed that LA treatment increased
phosphorylation of Lck, a downstream effector of protein kinase A. Pretreatment with a peptide inhibitor of PKA, PKI,
blocked LA inhibition of IL-2 and IFN gamma production, indicating that PKA mediates these responses. Oral administration
of 1200 mg LA to MS subjects resulted in increased cAMP levels in PBMCs four hours after ingestion. Average cAMP levels in
20 subjects were 43% higher than baseline.
Conclusions/Significance: Oral administration of LA in vivo resulted in significant increases in cAMP concentration. The anti-
inflammatory effects of LA are mediated in part by the cAMP/PKA signaling cascade. These novel findings enhance our
understanding of the mechanisms of action of LA.
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Introduction
Multiple sclerosis (MS) is a chronic disease of unknown etiology
that affects the central nervous system (CNS) and is characterized
by inflammation, demyelination and destruction of oligodendro-
cytes and axons. The immunology of MS is complex, involving
autoreactive Th1 and Th17 lymphocytes, cells of the innate
immune system including dendritic, natural killer (NK) and
microglia cells, as well as vascular endothelial cells [1]. These
cells produce an array of proinflammatory cytokines and
chemokines such as interleukin (IL)-17, interferon (IFN)-c,
CCL5, CXCR3 and CXCL10 that contribute to disease
pathogenesis [2]. Current FDA approved disease modifying
therapies for MS such as beta interferon, glatiramer acetate and
natalizumab are only partially effective and cause side-effects.
Thus, there is a need for the continued development of new
treatment strategies and targets for successful management of MS.
There is increasing interest in the use of antioxidants, such as
lipoic acid (LA), for the treatment of MS and other inflammatory
diseases.
LA is a small molecule fatty acid that is endogenously
synthesized and functions in vivo as a cofactor for many
mitochondrial dehydrogenase enzymes such as pyruvate dehydro-
genase [3,4]. Exogenous sources of LA have been shown to exhibit
both antioxidant and anti-inflammatory properties. LA inhibits
vascular cell adhesion molecule (VCAM)-1 and intercellular
adhesion molecule (ICAM)-1 production [5,6], downregulates
surface CD4 expression on blood mononuclear cells [7],
attenuates tumor necrosis factor (TNF)-a and monocyte chemoat-
tractant protein (MCP)-1 secretion [8], and inhibits NK cell
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that LA suppresses experimental autoimmune encephalomyelitis
(EAE) in SJL mice [10]. Two independent groups have since
reported similar findings in both mouse and rat models of EAE
[11,12]. These investigations showed reduced T cell and
macrophage infiltration into the CNS and spinal cords, decreased
demyelination and axonal damage, reduction in both Th1 and
Th2 cytokines including IL-4 and IFNc, inhibition of matrix
metalloproteinase (MMP) 2 and MMP9 proteolytic activity,
reduced ICAM-1 and VCAM-1 expression, and prevention of
blood brain barrier permeability [5,10,11,12,13]. Furthermore, a
pilot study by Yadav et al. demonstrated that oral ingestion of LA is
safe in MS subjects and resulted in reduced serum MMP9 and
sICAM-1 levels [14]. However, the cellular and biochemical
mechanisms that mediate the anti-inflammatory effects of LA are
not fully understood.
We first reported the novel finding that LA stimulates cAMP
production in human T lymphocytes, NK cells and PBMCs in vitro
[9,15]. It is well documented that cAMP is able to act as an
immunomodulator. Activation of the cAMP dependent signaling
pathway may contribute to the generation of Th2 lymphocytes by
providing a strong inhibitory signal for Th1 cytokines, whereas
Th2 cytokines are either unaffected or upregulated by this signal
transduction system [16]. For example, increased cAMP levels
stimulated by phorbol-myristate acetate plus the calcium iono-
phore A23187 in T cell lines had no effect on IL-4 mRNA
expression, but inhibited IL-2 mRNA expression [17]. Similarly,
increased cAMP levels in Th2 and Th0 clones treated with
prostaglandin E2 (PGE2) had no effect on IL-4 production while
IL-5 synthesis was inhibited. In contrast, production of IFNc and
IL-2 from Th1 clones were consistently inhibited by PGE2 [18,19].
cAMP is a small molecule second messenger mediating signal
transduction initiated by ligand binding to G-protein coupled
receptors, such as histamine, prostaglandin and adrenergic
receptors, and subsequent activation of adenylyl cyclases. cAMP
activates protein kinase A (PKA) by binding to the regulatory
subunits of PKA, releasing the catalytic subunits from inhibition,
and allowing the phosphorylation of various downstream targets,
including Lck [20]. Due to the large number of ligands and
GPCRs available, cAMP, via activation of PKA, is involved in
regulating many physiological and pathophysiological processes.
In this study, we present evidence demonstrating that LA
treatment inhibited IL-6 and IL-17 production and decreased T
cell proliferation and activation. LA appeared to have a biphasic
effect on IL-10 secretion, however the data is not statistically
significant. We also show that incubation with LA resulted in
activation of PKA signaling and that blocking PKA using PKI
inhibited LA mediated suppression of T cell and NK cell
activation. Furthermore, we show for the first time that cAMP
levels are elevated in PBMCs obtained from MS subjects four
hours after oral ingestion of 1200 mg LA.
Results
LA reduces IL-6 and IL-17 secretion
Naı ¨ve CD4
+ T helper (Th) cells are able to undergo
differentiation to specific lineages depending on the local cytokine
environment. Recent studies in EAE suggest that Th17 cells play a
crucial role in the pathogenesis of the disease [21]. We and others
have shown that LA has anti-inflammatory properties in part by
inhibiting production of some pro-inflammatory cytokines
[5,6,8,9]. However, it is not known how LA treatment will affect
the synthesis of interleukin (IL)-6 and IL-17, which are involved in
Th17 cell differentiation and function. We show that LA reduces
IL-6 production in a dose-dependent manner (Fig. 1A). T cell
enriched PBMCs were pretreated with 0, 50 or 100 mg/ml LA for
5 minutes prior to stimulation with 5 mg/ml LPS for 6 hours at
37uC. Supernatants were collected and used to measure IL-6 levels
via ELISA. Treatment with LPS significantly increased IL-6
production compared to untreated controls. Pretreatment with 50
and 100 mg/ml LA prior to LPS stimulation resulted in reduced
IL-6 levels by 19 and 34%, respectively.
IL-17 levels were also reduced upon pre-incubation with LA
(Fig. 1B). T cell enriched PBMCs were incubated with 0, 50 or
100 mg/ml LA for 5 minutes. Cells were then treated with
4 mg/ml anti-CD3 and 2 mg/ml anti-CD28 for 24 hours at
37uC and supernatants were collected for analysis. Stimulation
with anti-CD3/CD28 resulted in dramatic and statistically
significant increases in IL-17 levels compared to untreated
controls. Pretreatment with 50 and 100 mg/ml LA inhibited IL-
17 production by 35 and 50%, respectively. Collectively, these
Figure 1. LA treatment suppresses the production of cytokines
involved in Th17 T cell differentiation and activation. (A) T cell
enriched PBMCs were pretreated with 50 or 100 mg/ml LA for 5 minutes
and then stimulated with 5 mg/ml LPS for 6 hours. The supernatants
were used to measure IL-6 levels via ELISA (R&D Systems, Minneapolis,
MN). N=3 donors in triplicate. * indicates significance compared to LPS
control (p,0.05). (B) T cell enriched PBMCs were pretreated with
LA prior to stimulation with a combination of 4 mg/ml anti-CD3 and
2 mg/ml anti-CD28 for 24 hours. Supernatants were used to measure IL-
17 levels (eBiosciences, San Diego, CA). Depicted is a representative of 3
donors in triplicate. * indicates statistical significance compared to anti-
CD3/CD28 control (p,0.05).
doi:10.1371/journal.pone.0013058.g001
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inhibiting IL-6 and IL-17 synthesis.
LA inhibits T cell proliferation and activation
LA prevents inflammatory T cell migration into the spinal cords
of mice and rats with EAE [5,12]. Here, we examined the effects of
LA on human T cell proliferation and activation. T cell enriched
PBMCs were incubated with LA prior to stimulation with anti-
CD3 and anti-CD28. Proliferation was measured using
3H-
thymidine incorporation while IL-2 production was used to
measure T cell activation. Stimulation with anti-CD3/CD28
resulted in a significant and dramatic increase in
3H-thymidine
incorporation compared to untreated cells (Fig. 2A). Pretreatment
with 10 mg/ml LA inhibited
3H-thymidine incorporation by
approximately 90% while 50 mg/ml LA completely abolished
3H-thymidine incorporation. Treatment with anti-CD3/CD28
also stimulated IL-2 production (Fig. 2B). Pretreatment with
50 mg/ml LA reduced IL-2 levels by approximately 50%.
Collectively, the data presented here indicate that LA inhibits T
cell proliferation and activation.
Effect of LA on IL-10 production
In the previous figures, we showed that LA inhibited production
of pro-inflammatory cytokines. We next determined the effects of
LA on production of the anti-inflammatory cytokine IL-10, which
is produced by monocytes and lymphocytes and has been shown to
be a mediator of the therapeutic effects of various treatments in
EAE [22,23]. IL-10 levels have also been shown to be elevated in
the serum of MS patients after treatment with methylprednisolone
[24]. There are reports that cAMP elevating agents increase IL-10
synthesis [25,26,27]. However, others have shown that cAMP
decreases IL-10 production [28,29]. To determine the effects of
LA on IL-10 production, we first treated T cell enriched PBMCs
with varying concentrations of LA, however, LA alone did not
stimulate IL-10 production (data not shown). There are reports
that the effects of cAMP elevating agents are only detected
following T cell stimulation [30,31]. As such, we determined the
effects of LA on IL-10 synthesis after stimulation with PHA. T cell
enriched PBMCs were incubated with 10, 25 or 100 mg/ml LA for
5 minutes then stimulated with 2 mg/ml PHA for 24 hours. The
average basal IL-10 levels were 11.4% of PHA stimulated control
(Fig. 3). The addition of LA resulted in a biphasic effect on IL-10
production, although the results are not statistically significant. In
the presence of 10 or 25 mg/ml LA, PHA stimulation resulted in
increased IL-10 levels compared to PHA only.. Treatment with
100 mg/ml LA appeared to decrease IL-10 levels. Collectively, the
cytokine data suggest that LA is exerting its anti-inflammatory
effects by lowering the concentrations of pro-inflammatory
cytokines (IL-6 and IL-17) while possibly having a biphasic effect
on IL-10.
LA activates PKA signal transduction
We have shown that LA inhibits pro-inflammatory cytokine
production and T cell activation. However, the biochemical
mechanisms that mediate the anti-inflammatory actions of LA are
not fully understood. We previously reported that LA stimulates
cAMP production in inflammatory cells [9,15]. cAMP is a second
messenger that activates many signaling cascades, one of which is
the Protein Kinase A (PKA) pathway [32]. PKA activation
regulates a variety of eukaryotic cell functions, including T cell
activation [33]. One established inhibitory PKA signaling pathway
in T cells is PKA phosphorylation of Src kinase, which in turn
phosphorylates and deactivates Lck, a protein required for T-cell
receptor activation. To determine if LA induced cAMP produc-
tion leads to stimulation of this inhibitory pathway, we examined
the effects of LA on Lck phosphorylation. Western blot analysis
revealed increased phospho-Lck (pLck) levels after treatment with
LA for 10 minutes compared to untreated control (Fig. 4A, top
panel). No changes were detected in total Lck levels in the absence
or presence of LA. Densitometric analysis revealed that LA
increased pLck levels by approximately 30% (Fig. 4B).
We next determined if PKA mediates the effects of LA on T cell
activation. T cell enriched PBMCs were incubated for 30 minutes
with 100 mM PKI, a peptide that inhibits PKA by acting as a
pseudosubstrate. Cells were then treated with 25 mg/ml LA for
5 minutes prior to stimulation with anti-CD3/CD28 for 24 hours.
Figure 2. Treatment with LA attenuates T cell proliferation and
activation. (A) T cell enriched PBMCs were pretreated with LA prior to
stimulation with anti-CD3/CD28 for 72 hours. Proliferation was mea-
sured using 3H-Thymidine incorporation. N=3. *indicates statistical
significance compared to anti-CD3/CD28 control (p,0.05). (B) T cell
enriched PBMCs were stimulated in triplicate with anti-CD3 (4 mg/ml,
OKT3) and soluble anti-CD28 (5 mg/ml, BD Pharmingen) in the presence
or absence of 50 mg/ml LA (1 minute pretreatment). Cells were then
incubated for 6 hours at 37uC, 5% CO2. Supernatants were collected
and IL-2 levels were analyzed by ELISA (R&D Systems, Minneapolis, MN).
N=3. *indicates statistical significance compared to anti-CD3/CD28
control (p,0.05).
doi:10.1371/journal.pone.0013058.g002
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controls and pretreatment with PKI blocked this inhibition
(Fig. 5A). Treatment with PKI alone did not statistically alter
anti-CD3/CD28 induced IL-2 production (data not shown).
To determine if the effects of PKI are specific to T cells, we
conducted experiments in a different model looking at the effects
of LA on NK cell activation. We previously reported that LA
inhibits NK cell activation by blocking IFNc production [9]. NK
cells were incubated with PKI for 30 minutes prior to treatment
with LA. Cells were then stimulated with 10 ng/ml IL-12/IL-18
for 24 hours and NK cell activation was determined by measuring
IFNc production. We showed that LA completely blocked IFNc
production compared to IL-12/IL-18 stimulated control (Fig. 5B).
Similar to IL-2, pretreatment with PKI completely blocked IFNc
inhibition by LA. Collectively, the data demonstrates that LA
activates the PKA signaling cascade to modulate T cell and NK
cell activation.
LA stimulates cAMP production in MS patients
Up until this point, all experiments looking at the effects of LA
on cAMP levels have been performed in cells in vitro. To determine
if LA is able to stimulate cAMP production in vivo in human
subjects with multiple sclerosis, thirty-six subjects were screened
and 29 were randomized to receive 1 of 3 formulations of LA: A, B
or C. The formulations differ in composition and were obtained
from different companies (see materials and methods). Five
subjects withdrew from the study, leaving 24 subjects who
completed the study. See Table 1 for subject demographics
(modified from [34]). Blood was drawn before (T0) and 4 hours
after oral ingestion of LA (T4). A 1200 mg dosage of racemic LA
was used (50:50 mixture of R and S enantiomers). The 1200 mg
dosage was found to be safe in a pilot study conducted by Yadav
et al. [14]. Of the 24 remaining subjects, cAMP analyses on
PBMCs were obtained from 20 subjects; the serum was
contaminated for 1 subject and not enough cells were collected
for the other 3 subjects. The average cAMP data for all 20
participants is shown in Fig. 6A. Baseline cAMP level (T0) was
8.6560.79 pmol/mg protein (Table 1). Administration of LA
resulted in a 43% increase in cAMP level (15.71 pmol/mg protein)
compared to baseline. Figure 6B shows the cAMP data for each of
the LA formulations administered. Formulation A, B and C
resulted in increased cAMP levels by 57, 38.7 and 14.9%,
respectively, compared to baseline. The data presented here is the
first to show that oral administration of LA results in elevated
cAMP levels in vivo.
Discussion
Inflammation is a critical component of MS involving T cells,
antigen-presenting cells, cells of the innate immune system such as
NK cells, and cells of the CNS such as microglia, astrocytes and
neurons. These cells produce a cytokine milieu, including IL-6 and
IL-17, which perpetuate the inflammatory response. IL-17
producing Th17 cells are now believed to be the major pathogenic
T cell subset in EAE/MS and other autoimmune diseases [35,36],
although cause and effect relationships in human health have not
been established. IL-6 is a pleiotropic cytokine with a variety of
functions, but of importance for this study, IL-6 is an essential
differentiation factor for Th17 cells [37,38]. Both IL-6 and IL-17
mRNA have been shown to be highly expressed in MS lesions
[39]. Elevated IL-17 levels in the serum and cerebrospinal fluid of
MS patients have also been reported [40]. In EAE, wild-type mice
developed encephalitogenic peptide pMOG 35–55 induced EAE,
whereas IL-6 deficient mice are resistant to the disease [41].
Blockade of IL-6 using an anti-IL-6 receptor monoclonal antibody
inhibited the development of EAE and the induction of myelin
Figure 3. LA appears to have a biphasic effect on IL-10
production. T cell enriched PBMCs were treated with 10, 25, or
100 mg/ml LA for 5 minutes prior to treatment with 2 mg/ml PHA for
24 hours. Supernatants were used to measure IL-10 levels via ELISA
(R&D systems, Minneapolis, MN). Percent change values were deter-
mined from PHA stimulated control. Depicted is the average of at least
3 donors in triplicate.
doi:10.1371/journal.pone.0013058.g003
Figure 4. LA activates the protein kinase A (PKA) signaling
pathway. (A) T cells were stimulated with 10 mg/ml LA for 10 min.
Total protein was harvested and used for western blot analysis for Lck
phosphorylation, which is a downstream effector of PKA signaling. The
top blot is phospho-Lck and the bottom panel is Lck. (B) Graphical
representation of densitometric analysis of band intensity showing the
ratio of pLck/Lck. N=9. *indicates statistical significance compared to
untreated control (p,0.05).
doi:10.1371/journal.pone.0013058.g004
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Th17 T cells [42], indicating the protective effect of IL-6 blockade
may be due to reducing the infiltration of autoreactive T cells into
the CNS. In this study we show that LA inhibits IL-6 and IL-17
production in human PBMCs, suggesting that LA has the potential
to be therapeutic in MS. It will be exciting to see if administration
of LA to MS subjects will result in reduction in IL-6 and IL-17
levels in the serum and in circulating PBMCs.
To stimulate IL-6 production, we used LPS, which is a ligand
for toll-like receptor 4 (TLR-4). The TLR-4 pathway leads to
downstream activation of the transcription factor nuclear factor
kappa B (NF-kB) and pro-inflammatory gene expression. How can
LA, via cAMP/PKA signaling, affect the LPS/TLR-4 pathway?
There are several reports supporting the idea that there is crosstalk
between the two signaling pathways. Wall et al. demonstrated that
cAMP/PKA inhibits NF-kB function by slowing down its
translocation into the nucleus and preventing gene transcription
[27]. Parry and Mackman also showed that cAMP/PKA inhibits
NF-kB activity [43]. It is therefore possible that LA is inhibiting
LPS induced NF-kB activity, thus reducing IL-6 production via
activation of PKA. Although we show statistically significant
Figure 5. Pretreatment with PKI blocked the suppression of T
cell and NK cell activation by LA. (A) T cell enriched PBMCs were
incubated in 100 mM PKI for 30 min prior to treatment with 25 mg/ml
LA for 5 min. Cells were then treated with 4 mg/ml anti-CD3/CD28 for
24 hours. Supernatants were collected and IL-2 levels were measured
via ELISA (eBioscience, San Diego, CA). N=3 donors in triplicate.
*indicates statistical significance compared to anti-CD3/CD28 stimulat-
ed control. **indicates significance compared to LA plus anti-CD3/CD28
(p,0.05). (B) Purified NK cells were pretreated with 100 mM PKI for
30 min prior to treatment with LA for 5 min. Cells were then stimulated
with 10 ng/ml IL-12/IL-18 for 6 hours. Supernatants were used to
measure IFN gamma levels via ELISA (R&D systems, Minneapolis, MN).
*indicates statistical significance compared to IL-12/IL-18 stimulated
control. **indicates significance compared to LA plus IL-12/IL-18
(p,0.05).
doi:10.1371/journal.pone.0013058.g005
Figure 6. Oral administration of LA stimulates cAMP produc-
tion in MS patients. (A) PBMCs were isolated from blood drawn from
MS patients before (T0) and 4 hours (T4) after oral ingestion of 1200 mg
racemic (50:50 mixture of R and S enantiomers) LA. Previously frozen
PBMCs were resuspended in 100 ml PBS. Fifty ml were transferred to new
tubes then lysed in additional 350 ml 0.1 M HCl and boiled for 10 min.
Samples were pelleted by centrifugation at 13006g for 1 min. The
supernatants were used for measuring cAMP levels via ELISA (Assay
Designs, Ann Arbor, MI). N=20 subjects in duplicate. *indicates
statistical significance compared to T0 (p,0.05). (B) Subdividing (A)
into groups according to the LA formulations received: formulation A, B
or C. See Methods and Materials for a description of each formulation.
*indicates statistical significance compared to T0 (p,0.05).
doi:10.1371/journal.pone.0013058.g006
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that a large amount of IL-6 is still produced in response to LPS
stimulation (Fig. 1a) indicating that IL-6 can still modulate the
inflammatory response in general and, specifically, the cellular
response to toll-like receptor (TLR)-4 ligands. This may be
advantageous since a common side effect of immunosuppressive
drugs is increased susceptibility to infections. If IL-6 is available in
the circulation, the host is still able to fight off infections.
LA has been shown to be therapeutic in EAE [10,12,44].
Several reports demonstrated inhibition of T cell migration in vitro
and into the spinal cord of EAE animals treated with LA [10,12].
However, very little is known about the effects of LA and its
mechanisms of action in human diseases. LA has antioxidant
properties where it scavenges reactive oxygen and nitrogen species
and replenishes glutathione and other endogenous antioxidants
[45]. More recently, we and others have shown that LA exhibits a
non-redox anti-inflammatory role [7,9,10,11], probably via
modulation of various signaling cascades that mediate these
processes. For instance, LA stimulates theproduction of the
immunomodulator cAMP in human inflammatory cells via
activation of the prostaglandin E2 (PGE2) EP2 and EP4 receptors
[9,15]. This is likely possible due to the fact that LA shares some
structural similarities to PGE2 and they are both hydrophobic and
can exist in multiple conformers. For detailed discussion, we refer
readers to our previous publication [9].
In this study, we determined that LA decreased
3H-thymidine
incorporation and IL-2 production, indicating that LA inhibits T
cell proliferation and activation. This is consistent with other
reports using an assortment of cAMP elevating agents
[46,47,48,49]. For example, pretreatment with cholera toxin,
forskolin, PGE2 or dibutyryl-cAMP reduced IL-2 levels in murine
CD4+ T cells [47]. Similarly, isoproterenol inhibited concanavalin
A induced IL-2 secretion in T cells obtained from both asthmatic
and non-asthmatic subjects [46]. Since MS/EAE is believed to be
a T cell mediated disease, the ability of LA to inhibit T cell
proliferation and activation may explain how LA can treat and
prevent EAE and possibly MS.
In many autoimmune disease models, IL-10 has been shown to
be protective [37,50]. IL-10 is a homodimeric pleiotropic cytokine
that is produced by numerous cell types including monocytes,
macrophages, neutrophils and T cells [51] and can exert its anti-
inflammatory effects on both myeloid and lymphoid cells [37]. IL-
10 inhibits the development of Th1 type responses, exerts
autocrine inhibitory effects on macrophages and DCs, and
enhances the differentiation of IL-10 secreting T regulatory cells
to provide a positive regulatory loop for its induction [51]. Here,
we report that LA treatment has a biphasic effect on IL-10
secretion, although the data is not statistically significant. This is
not a unique phenomenon. Franchimont et al. showed increased
IL-10 levels using low concentrations of dexamethasone and
decreased IL-10 levels to below baseline with higher doses of
dexamethasone [52] The IL-10 promoter contains cAMP-
responsive elements, which are bound by cAMP responsive
element binding (CREB) protein, and myocyte enhancer factor
(MEF)-2 binding sites. PHA stimulates T cells via cross-linking
CD3 and the TCR complex [53,54], which in turn activates MEF-
2 [29]. cAMP leads to downstream activation of CREB. Binding of
CREB or MEF-2 to the promoter results in increased IL-10
production [27,29]. cAMP, however, has been shown to inhibit
MEF-2 binding to the IL-10 promoter, thus inhibiting IL-10
synthesis [29]. It is possible that low LA concentrations stimulate
CREB binding to the promoter to increase IL-10 production while
high cAMP levels are interfering with MEF-2 binding, thus
resulting in decreased IL-10 levels. Future studies will be
undertaken to determine if this is true.
cAMP is a small molecule second messenger involved in
activation of various signaling pathways. Generation of cAMP is
mediated by activation of G-protein coupled receptors and
subsequent activation of transmembrane and soluble adenylyl
cyclases (tmAC and sAC, respectively) [55,56,57]. cAMP, in turn,
activates downstream signaling cascades, the most studied being
the serine/threonine protein kinase, PKA, pathway. PKA is
ubiquitously expressed and is composed of four subunits: two
catalytic subunits and a dimer of regulatory subunits [33]. Upon
Table 1. Baseline demographics and cAMP response in MS subjects.
Formulation A Formulation B Formulation C Total
Number in group (n) 888 2 4
Gender Male 3 3 1 7
Female 5 5 7 17
Age (years) Median 48.5 52 50.5 51
Range 36–66 27–77 42–65 27–77
Race Caucasian 8 8 8 24
Non-caucasian 0 0 0 0
Type of MS Relapsing-remitting 4 3 5 12
Primary progressive 1 0 0 1
Secondary progressive 3 5 3 11
MS duration (years) Median 11.5 21 11.5 12.5
Range 1.0–16.0 8.0–33.0 2.0–35.0 1.0–35.0
EDSS Median 4.0 5.0 4.0 4.0
Range 2.0–7.0 2.5–7.5 2.0–8.0 2.0–8.0
cAMP Response T0 (pmol/mg protein) 7.1861.02 (6) 10.3961.67 (7) 10.0361.13 (7) 8.6560.79 (20)
T4 (pmol/mg protein) 16.7264.4 16.9362.36 10.0460.63 15.1861.71
Modified from [34]. For cAMP response, the numbers in parentheses indicate number of samples measured.
doi:10.1371/journal.pone.0013058.t001
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catalytic subunits, and thereby activated. In T cells, PKA can
inhibit cell activation by phosphorylating C-terminal Src kinase
(Csk) which phosphorylates and deactivates Lck, a protein
necessary for T cell receptor activation [32,33]. Our data suggest
that LA activates PKA leading to Lck phosphorylation and
deactivation. Employing a different method, Marracci et al.
showed that LA treatment dissociates Lck from CD4 in Jurkat
cells leading to down-modulation of surface CD4 expression [7].
To confirm that PKA mediates the effects of LA, experiments
were performed to determine the effects of blocking PKA
activation on LA function. A variety of inhibitors are available
that can be used to inhibit PKA activity. In this study we used
PKI, a 21 amino acid peptide which acts as a pseudosubstrate of
PKA. Pretreatment of T cells with a cell permeable PKI peptide
prior to incubation with LA and stimulation with anti-CD3/CD28
blocked the attenuation of IL-2 production (T cell activation) by
LA. Similarly, PKI ameliorated LA mediated suppression of IFNc
synthesis in NK cells indicating that LA induced activation of PKA
is not confined to T cells. These data show that LA modulation of
immune cell function is mediated in part via activation of PKA
signaling. In figure 7, we illustrate the molecules that we have
shown to mediate the effects of LA. LA binds the EP2/EP4
receptors to activate tmACs, which in turn generate cAMP. cAMP
leads to activation of PKA signaling and inhibition of immune cell
function.
The in vitro data demonstrating modulation of cAMP production
and the immune response by LA is now supported by in vivo data.
This study is the first to show the effects of LA on cAMP
production in vivo. We demonstrated that a 1200 mg dose of LA
given orally increased average cAMP levels by 43% in PBMCs
obtained from subjects with MS. This dosage is well tolerated and
considered safe [14]. Subdividing the data into groups according
to the different formulations given illustrates that formulation A
and B elicited a robust increase in cAMP (57 and 38.7% increase,
respectively), whereas the increase in cAMP levels resulting from
ingestion of formulation C were more modest (14.9% increase). It
is possible that the difference in response is due to varying
absorption rates of LA. A recent publication analyzing the
pharmacokinetics of serum LA concentration in the same subjects
presented in this study demonstrates that serum LA concentrations
peaked at an earlier time point (about 30 minutes faster) for
formulation C compared to formulations A or B [34]. Since
absorption rate is determined by the rate of dissolution of a
compound, its formulation may influence this process depending
on the conditions of the gastrointestinal environment, such as pH,
intestinal flora and enzyme content [58]. Furthermore, because
cAMP levels are transient, four hours post ingestion may have
been too late to detect increased cAMP levels for formulation C.
Future studies looking at the kinetics of cAMP levels at the same
time points used for determining the pharmacokinetics of LA will
allow us to better correlate the peak cAMP response to peak serum
LA concentration.
Components other than LA are present in the tablets/capsules
being ingested. Is it possible that these additives are regulating
cAMP production? While we cannot eliminate other components,
it is unlikely that ascorbic acid, which is the most abundant
additive in formulations B and C, is responsible for the elevation in
cAMP levels. In vitro studies in PBMCs indicate that ascorbic acid
treatment does not result in increased cAMP production
(unpublished data). Future studies utilizing the appropriate
placebo controls will determine that cAMP production is a specific
response to LA treatment.
Administration of LA is therapeutically effective in diabetic
polyneuropathy and other diseases [59,60,61]. A pilot study in MS
patients demonstrated that oral administration of LA for two
weeks resulted in decreased amounts of matrix metalloproteinase-9
and soluble ICAM-1, markers of inflammatory activity, in the
serum [14]. The ability of LA to stimulate cAMP production is
also encouraging since cAMP and components of its signaling
cascade have been therapeutic targets. For instance, phosphodi-
esterase inhibitors such as milrinone, which prevents the
breakdown of cAMP thereby increasing its intracellular concen-
tration, is used to treat coronary heart disease [62]. Forskolin, a
non-specific cAMP elevating agent produced from the plant Coleus
forskohlii, is also being pursued for medicinal purposes. Cell culture
and animal studies have shown that forskolin has anti-inflamma-
tory effects similar to LA. For instance, forskolin and its derivatives
inhibit T cell proliferation and activation, as well as attenuate
proinflammatory cytokine production [63,64,65]. However, it has
not yet been determined if forskolin is able to stimulate cAMP
production in vivo or if forskolin is bioloigically available since it has
low water solubility. LA, on the other hand, is biologically
available in vivo [45]. LA is also considered safe, is produced
endogenously in human beings and has antioxidant properties that
may contribute to its beneficial therapeutic effects [14,45].
In summary, we show that LA exhibits anti-inflammatory
properties by inhibiting IL-6 and IL-17 production and T cell
proliferation and activation while possibly maintaining IL-10
synthesis. In addition, LA activates the PKA signaling pathway.
We also show for the first time that oral ingestion of LA tablets/
capsules lead to elevated cAMP levels in vivo. These data provide a
foundation for future studies, both in vitro and in MS patients, to
determine the therapeutic potential of LA.
Materials and Methods
Materials and Reagents
RPMI, fetal bovine serum and all other tissue culture reagents
were purchased from Invitrogen (Carlsbad, CA). The EasySep NK
cell negative purification kit was purchased from Stem Cell
Technologies Inc. (Vancouver, British Columbia). The cAMP kits
were purchased from BioAssay Designs (Ann Arbor, MI). The
BCA protein assay kit was obtained from Pierce Biotechnology
Figure 7. Schematic illustration of the putative LA signaling
events. LA binds to the EP2 and EP4 receptors to activate the Gs
subunit of the trimeric G-proteins. Gs activates adenylyl cyclase (AC),
which generates cAMP from ATP. AC is degraded by phosphodiester-
ases (PDEs) into AMP and Pi. cAMP activates the PKA signaling cascade
leading to inhibition of immune cell function. PKI acts as a
pseudosubstrate to inhibit PKA signaling.
doi:10.1371/journal.pone.0013058.g007
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Systems (Minneapolis, MN) or Ebioscience (San Diego, CA). LA
for in vitro studies was purchased from Sigma (St. Louis, MO). For
in vivo studies, LA was obtained from three sources: Viatris
(formulation A), Vital Nutrients (formulation B) or Pure Encap-
sulations (formulation C). Pure EncapsulationsH (Sudbury, MA,
USA) provided vegetable capsules containing 600 mg LA (Lot #
3480504 expiration 11/06). Each 600 mg LA capsule contained
30 mg of vitamin C (ascorbyl palmitate derived from corn
dextrose fermentation) and pine cellulose plant fiber to add to
volume. Vital NutrientsH (Middletown, CT, USA) provided
gelatin capsules containing 300 mg LA (lot # 5G24 expiration
08/07). Each also contained cellulose powder (may contain
Ascorbyl Palmitate and/or Silica). ViatrisH (now called Meda
PharmaH) LA was a tablet formulation containing 600 mg LA (lot
# 4E002-1, expiration date 05/07).
Human Subjects
The study received approval from the Oregon Health & Science
University (OHSU) Institutional Review Board prior to initiation.
All subjects gave written informed consent prior to participation in
the study. To qualify, subjects needed to meet the following
inclusion/exclusion criteria: definite MS by McDonald’s [66] or
Poser’s criteria [67], EDSS#7.5 [68]; age 18–70 inclusive; no
clinically significant MS exacerbation within 30 days of the
screening; no systemically administered corticosteroids within 30
days of study entry; female subjects were not pregnant or breast-
feeding; no LA in previous 2 weeks; subjects were not on anti
coagulants such as heparin or coumadin or aspirin during the
study; and subjects did not have other significant health problems
(e.g. active coronary heart disease, liver disease, pulmonary
disease, diabetes mellitus) that could increase risk of experiencing
adverse events or was unable to give informed consent. Subjects
were allowed to receive symptomatic medications while on study.
Subjects who took aspirin were asked to stop aspirin 7 days prior to
the study. Subjects taking recombinant interferon (IFN)-b or
glatiramer acetate were allowed to continue taking these
medications. Subjects were randomized to receive one of three
treatment arms: formulation A, B or C. Blood draws were
obtained for subjects at baseline (T=0) and four hours after oral
ingestion of LA (T=4). Cells and serum were separated via
centrifugation. PBMCs were isolated from total cells through ficoll
purification similar to steps described below. PBMCs were
aliquoted and frozen down in liquid nitrogen for future use.
Cell culture
Human PBMCs were obtained from source leukocytes (buffy
coat) from the Red Cross in Portland, OR (approval #VACARR)
or apheresis products purchased from Keybiologics (Memphis,
TN). For buffy coats, enriched leukocytes were subjected to ficoll
purification (Amersham) and centrifugation at 1400 rpm with the
brake turned off for 30 minutes to remove contaminating red
blood cells and platelets. The interface was collected, washed with
RPMI 1640 and centrifuged at 1300 rpm for 10 minutes. The
supernatant was decanted and the cells were subjected to two
more wash steps. Cells were resuspended in freezing medium
(RPMI+25% FCS+12% DMSO) and stored in liquid nitrogen for
future use. For apheresis products, blood was split into conical
tubes, diluted with 46 volume with 16 PBS (no Ca
2+ or Mg
2+),
and centrifuged at 2006g for 15 min at RT. Supernatants were
pipetted off the top (pellet is very loose), cells were resuspended in
a small volume of PBS by flicking the tube, and fresh PBS (50 ml)
was added. Cells were centrifuged at 2006g for 15 min at RT.
This wash step was repeated once more. Cells were then subjected
to ficoll gradient purification and frozen down as described above
for buffy coats.
Previously frozen PBMCs were thawed and NK cells purified
using the EasySep negative purification kit following the
manufacture’s protocol. Briefly, human NK cell enrichment
cocktail (50 ml/ml cells) was added to PBMCs (2610
7 cells/ml)
in PBS+2% FBS and 1 mM EDTA and incubated at RT for
10 min. EasySep magnetic microparticles (100 ml/ml cells) were
added to the cell mixture and incubated at RT for 5 min. The
total suspension was brought up to 2.5 mls with buffer and placed
into a magnet for 2.5 minutes. The supernatant containing the
purified NK cells was then collected for experiments.
ELISA
T cell enriched PBMCs (2610
6) were pretreated with the
indicated concentrations of LA for 5 minutes and then stimulated
in 14 ml falcon polypropylene tubes to determine IL-6, IL-10, IL-
17 and IL-2 levels via ELISA. For IL-6, cells were treated with
5 mg/ml LPS for 6 hours. A combination of 4 mg/ml anti-CD3
and 2 mg/ml anti-CD28 was used to stimulate cells for 24 hours
for IL-17. Two mg/ml PHA was used to stimulate IL-10
production for 24 hours. For IL-2, cells were stimulated in tubes
coated with anti-CD3 (4 mg/ml OKT3) and soluble anti-CD28
(5 mg/ml BD Pharmingen, Los Angeles, CA). Prior to stimulation,
cells were exposed to LA for one minute, rinsed and then added to
the tubes for stimulation. Supernatants were collected for each
treatment and used to measure cytokine levels using ELISA kits
purchased from R&D Systems (Minneapolis, MN) or Ebioscience
(San Diego, CA) following the manufacturer’s protocol. Endpoint
reading was determined by measuring the absorbance at 405 nm
on a colorimetric plate reader using Softmax Pro software
(Molecular Devices, Sunnyvale, CA).
Proliferation Assay
Proliferation assay was measured by [
3H]-thymidine incorpo-
ration. T cell enriched PBMCs (7.5610
4) were pretreated with 10
or 50 mg/ml LA for one minute prior to stimulation with
immobilized anti-CD3 and soluble anti-CD28. We previously
showed that we can achieve maximal LA stimulation of cAMP
production as early as 1 minute, with cAMP levels decreasing after
5 minutes [15]. After 48 hours of stimulation 10 ml[
3H]-
thymidine (50 mCi/ml) was added to the cells. 16 hours later cells
were collected and washed using a Tomtec cell harvester and glass
fiber membrane (Wallac). Incorporated tritium was determined by
scintillation counting.
Lck Phosphorylation
Two million PBMC were incubated with LA for one minute,
centrifuged (13506g 60s), rinsed with 500 ml RPMI 1640, and
centrifuged (13,0006g 60s). Cells were then lysed by boiling with
30 ml boiling SDS gel loading sample buffer. Ten ml of total cell
extract was subjected to SDS-PAGE and transferred to PVDF
membrane (Immobilon-P, Millipore). Membranes were blocked
with 5% milk TTBS for Lck Westerns and 3% BSA TTBS for Y-
505-pLck antibodies (Transduction laboratories, BD Pharmingen,
San Diego, Ca). HRP-conjugated goat anti-mouse (Santa Cruz
Biotech, Santa Cruz, CA) and Perkin-Elmer chemiluminescence
were used for detection (Boston, MA).
PKI Inhibition Assay
Poly-R-PKI (Biomatik Corporation, Wilmington, DE) was used
to determine if PKA signaling mediates the effects of LA on NK
cell and T cell activation. Poly-R PKI is a cell permeable peptide
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It acts as a pseudo-substrate that binds to the catalytic subunits of
PKA. Stocks were made by dissolving powder into water. For NK
cell activation, we measured IFNc production. NK cells (1610
5)
were pretreated with 100 mM PKI for 30 minutes then treated
with 50 mg/ml LA for 5 minutes. Cells were stimulated with a
mixture containing 10 ng/ml IL-12 and IL-18. Ten percent serum
was added 30 minutes after stimulation and incubated at 37uC for
a total of 24 hours. IFNc levels were determined by ELISA (R&D
Systems, Minneapolis, MN). A 96-well plate was coated with
100 ml aIFNc capture antibody (MAB2852) at 4 mg/ml and
incubated for 2 hours at 37uC. Wells were washed 5 times with
TTBS, blocked with 3% BSA/TTBS (200 ml) for 1 hour at RT
and washed again. Recombinant human IFNc standards (285-
IF100) or treated sample supernatants were added to each well
(100 ml) and incubated at RT for 2 hours. Wells were washed
with TTBS 56 and incubated with 100 ml biotinylated aIFNc
(200 ng/ml) (BAF285) for 2 hours at RT. After washing, wells
were incubated with 100 ml streptavidin-HRP for 20 minutes at
RT in the dark. Wells were washed with TTBS and incubated
with 100 ml TMB substrate (52-00-01) for 20 minutes at RT in the
dark. The reaction was stopped with the addition of 50 ml1 M
H2SO4 and absorbance was measured at 450 nm.
For IL-2, T cell enriched PBMCs (2610
6) were pretreated with
100 mM PKI for 30 minutes at 37uC. Cells were treated with
25 mg/ml LA for 5 minutes then stimulated with 4 mg/ml soluble,
human anti-CD3 (Zymed, San Francisco, CA) and anti-CD28
(Ancell, Bayport, MN) for 24 hours at 37uC. Ten percent serum
was added 30 minutes after stimulation. Supernatants were
collected after brief centrifugation and used for IL-2 ELISA
following manufacturer’s protocol (Ebioscience, San Diego, CA).
Absorbance reading was measured at 405 nm.
Cyclic AMP assay
Previously frozen PBMC obtained from human subjects
(between 5–7 million cells) were used for analysis of cAMP levels.
Pellets were resuspended in 100 ml cold 16 PBS on ice. Half of
that volume (50 ml) was transferred to a new tube containing
350 ml 0.1 M HCl. Cells were lysed by boiling for 10 minutes.
Samples were centrifuged at 1300 rpm and 100 ml of supernatants
were used for cAMP assays following the manufacture’s protocol.
The absorbance was measured at 405 nm using a colorimetric 96-
well plate reader. Results in pmol/ml were then divided by the
protein concentration (see BCA assay below) to obtain pmol of
cAMP per milligram of protein.
Bicinchoninic acid (BCA) assay
Ten microliters of supernatants from cAMP assays were used to
determine total protein concentrations using the BCA assay kit
(Pierce, Rockford, IL) following the manufacturer’s protocol.
Absorbance readings were measured at 562 nm. Bovine serum
albumin (BSA) standards were prepared in 0.1M HCl at
concentrations ranging from 0–1 mg/ml. Protein concentrations
for unknown samples were extrapolated from the standard curve
using Softmax Pro software (Molecular Devices, Sunnyvale, CA).
Statistical analysis
The data were analyzed using EXCEL 2007. The mean and
standard error of the mean were calculated. Statistics were
performed using Student’s t-test and were considered significant at
a p value of #0.05. All treatments were performed independently
at least 3 times.
Acknowledgments
We would like to thank Sarah Fiedler for helpful critique of the manuscript.
We would also like to thank Pure Encapsulations and Vital Nutrients for
donating their LA formulation products for these studies.
Author Contributions
Conceived and designed the experiments: SS VY RVS DB DWC.
Performed the experiments: SS VY RVS. Analyzed the data: SS VY RVS
DB DWC. Wrote the paper: SS VY RVS DB DWC.
References
1. Bhat R, Steinman L (2009) Innate and adaptive autoimmunity directed to the
central nervous system. Neuron 64: 123–132.
2. Agrawal SM, Yong VW (2007) Immunopathogenesis of multiple sclerosis. Int
Rev Neurobiol 79: 99–126.
3. Parry R (1983) Biosynthesis of some sulfur-containing natural products
investigations of the mechanism of carbon-sulfur bond formation. Tetrahedron
39: 1215–1238.
4. Perham RN (2000) Swinging arms and swinging domains in multifunctional
enzymes: catalytic machines for multistep reactions. Annu Rev Biochem 69:
961–1004.
5. Chaudhary P, Marracci GH, Bourdette DN (2006) Lipoic acid inhibits
expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell
migration into the spinal cord in experimental autoimmune encephalomyelitis.
J Neuroimmunol 175: 87–96.
6. Kunt T, Forst T, Wilhelm A, Tritschler H, Pfuetzner A, et al. (1999) Alpha-
lipoic acid reduces expression of vascular cell adhesion molecule-1 and
endothelial adhesion of human monocytes after stimulation with advanced
glycation end products. Clin Sci (Lond) 96: 75–82.
7. Marracci GH, Marquardt WE, Strehlow A, McKeon GP, Gross J, et al. (2006)
Lipoic acid downmodulates CD4 from human T lymphocytes by dissociation of
p56(Lck). Biochem Biophys Res Commun 344: 963–971.
8. Zhang WJ, Wei H, Hagen T, Frei B (2007) Alpha-lipoic acid attenuates
LPS-induced inflammatory responses by activating the phosphoinositide
3-kinase/Akt signaling pathway. Proc Natl Acad Sci U S A 104: 4077–
4082.
9. Salinthone S, Schillace RV, Marracci GH, Bourdette DN, Carr DW (2008)
Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid
receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells.
J Neuroimmunol 199: 46–55.
10. Marracci GH, Jones RE, McKeon GP, Bourdette DN (2002) Alpha lipoic acid
inhibits T cell migration into the spinal cord and suppresses and treats
experimental autoimmune encephalomyelitis. J Neuroimmunol 131: 104–
114.
11. Morini M, Roccatagliata L, Dell’Eva R, Pedemonte E, Furlan R, et al. (2004)
Alpha-lipoic acid is effective in prevention and treatment of experimental
autoimmune encephalomyelitis. J Neuroimmunol 148: 146–153.
12. Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, et al.
(2006) Lipoic acid affects cellular migration into the central nervous system and
stabilizes blood-brain barrier integrity. J Immunol 177: 2630–2637.
13. Marracci GH, McKeon GP, Marquardt WE, Winter RW, Riscoe MK, et al.
(2004) Alpha lipoic acid inhibits human T-cell migration: implications for
multiple sclerosis. J Neurosci Res 78: 362–370.
14. Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, et al. (2005) Lipoic
acid in multiple sclerosis: a pilot study. Mult Scler 11: 159–165.
15. Schillace RV, Pisenti N, Pattamanuch N, Galligan S, Marracci GH, et al. (2007)
Lipoic acid stimulates cAMP production in T lymphocytes and NK cells.
Biochem Biophys Res Commun 354: 259–264.
16. Borger P, Postma DS, Vellenga E, Kauffman HF (2000) Regulation of asthma-
related T-cell cytokines by the cyclic AMP-dependent signalling pathway. Clin
Exp Allergy 30: 920–926.
17. Novak TJ, Rothenberg EV (1990) cAMP inhibits induction of interleukin 2 but
not of interleukin 4 in T cells. Proc Natl Acad Sci U S A 87: 9353–9357.
18. Betz M, Fox BS (1991) Prostaglandin E2 inhibits production of Th1
lymphokines but not of Th2 lymphokines. J Immunol 146: 108–113.
19. Snijdewint FG, Kapsenberg ML, Wauben-Penris PJ, Bos JD (1995) Corticoste-
roids class-dependently inhibit in vitro Th1- and Th2-type cytokine production.
Immunopharmacology 29: 93–101.
20. Kamenetsky M, Middelhaufe S, Bank EM, Levin LR, Buck J, et al. (2006)
Molecular details of cAMP generation in mammalian cells: a tale of two systems.
J Mol Biol 362: 623–639.
21. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. (2006) The
orphan nuclear receptor RORgammat directs the differentiation program of
proinflammatory IL-17+ T helper cells. Cell 126: 1121–1133.
cAMP/PKA Modulates LA Function
PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e1305822. Lavasani S, Dzhambazov B, Nouri M, Fak F, Buske S, et al. A novel probiotic
mixture exerts a therapeutic effect on experimental autoimmune encephalomy-
elitis mediated by IL-10 producing regulatory T cells. PLoS One 5: e9009.
23. Yates MA, Li Y, Chlebeck P, Proctor T, Vandenbark AA, et al. Progesterone
treatment reduces disease severity and increases IL-10 in experimental
autoimmune encephalomyelitis. J Neuroimmunol 220: 136–139.
24. Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, et al.
(2008) Effect of treatment with methylprednisolone on the serum levels of IL-12,
IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clin
Neurol Neurosurg 110: 992–996.
25. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, et al. (1998)
Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10
synthesis and concurrent suppression of TNF production. J Leukoc Biol 63:
101–107.
26. Feng WG, Wang YB, Zhang JS, Wang XY, Li CL, et al. (2002) cAMP elevators
inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of
p38 MAPK in murine peritoneal macrophages. Cell Res 12: 331–337.
27. Wall EA, Zavzavadjian JR, Chang MS, Randhawa B, Zhu X, et al. (2009)
Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is
mediated by PKA-AKAP95-p105. Sci Signal 2: ra28.
28. Holm AM, Aukrust P, Aandahl EM, Muller F, Tasken K, et al. (2003) Impaired
secretion of IL-10 by T cells from patients with common variable immunode-
ficiency–involvement of protein kinase A type I. J Immunol 170: 5772–5777.
29. Liopeta K, Boubali S, Virgilio L, Thyphronitis G, Mavrothalassitis G, et al.
(2009) cAMP regulates IL-10 production by normal human T lymphocytes at
multiple levels: a potential role for MEF2. Mol Immunol 46: 345–354.
30. Goldsmith M, Avni D, Ernst O, Glucksam Y, Levy-Rimler G, et al. (2009)
Synergistic IL-10 induction by LPS and the ceramide-1-phosphate analog
PCERA-1 is mediated by the cAMP and p38 MAP kinase pathways. Mol
Immunol 46: 1979–1987.
31. Goldsmith M, Avni D, Levy-Rimler G, Mashiach R, Ernst O, et al. (2009) A
ceramide-1-phosphate analogue, PCERA-1, simultaneously suppresses tumour
necrosis factor-alpha and induces interleukin-10 production in activated
macrophages. Immunology 127: 103–115.
32. Tasken K, Stokka AJ (2006) The molecular machinery for cAMP-dependent
immunomodulation in T-cells. Biochem Soc Trans 34: 476–479.
33. Schillace RV, Carr DW (2006) The role of protein kinase A and A-kinase
anchoring proteins in modulating T-cell activation: progress and future
directions. Crit Rev Immunol 26: 113–131.
34. Yadav V, Marracci GH, Munar MY, Cherala G, Stuber LE, et al.
Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and
human pharmacokinetic parameters. Mult Scler 16: 387–397.
35. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23
rather than interleukin-12 is the critical cytokine for autoimmune inflammation
of the brain. Nature 421: 744–748.
36. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005)
IL-23 drives a pathogenic T cell population that induces autoimmune
inflammation. J Exp Med 201: 233–240.
37. Bettini M, Vignali DA (2009) Regulatory T cells and inhibitory cytokines in
autoimmunity. Curr Opin Immunol 21: 612–618.
38. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu
Rev Immunol 27: 485–517.
39. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, et al. (2002) Gene-
microarray analysis of multiple sclerosis lesions yields new targets validated in
autoimmune encephalomyelitis. Nat Med 8: 500–508.
40. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, et al. (1999)
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is
augmented in multiple sclerosis. Mult Scler 5: 101–104.
41. Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M (1998) Interleukin-6 functions
in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur J Immunol
28: 1727–1737.
42. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, et al. (2008) IL-6
blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1
cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A
105: 9041–9046.
43. Parry GC, Mackman N (1997) Role of cyclic AMP response element-binding
protein in cyclic AMP inhibition of NF-kappaB-mediated transcription.
J Immunol 159: 5450–5456.
44. Moini H, Packer L, Saris NE (2002) Antioxidant and prooxidant activities of
alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 182: 84–90.
45. Salinthone S, Yadav V, Bourdette DN, Carr DW (2008) Lipoic acid: a novel
therapeutic approach for multiple sclerosis and other chronic inflammatory
diseases of the CNS. Endocr Metab Immune Disord Drug Targets 8: 132–142.
46. Aihara M, Dobashi K, Horie T, Iizuka K, Nakazawa T, et al. (1999) Effects of
isoproterenol on IL-2 and cAMP production in peripheral T cells from
asthmatic and non-asthmatic subjects sensitive to Candida. Biol Cell 91:
525–531.
47. Lacour M, Arrighi JF, Muller KM, Carlberg C, Saurat JH, et al. (1994) cAMP
up-regulates IL-4 and IL-5 production from activated CD4+ T cells while
decreasing IL-2 release and NF-AT induction. Int Immunol 6: 1333–1343.
48. Rott O, Cash E, Fleischer B (1993) Phosphodiesterase inhibitor pentoxifylline, a
selective suppressor of T helper type 1- but not type 2-associated lymphokine
production, prevents induction of experimental autoimmune encephalomyelitis
in Lewis rats. Eur J Immunol 23: 1745–1751.
49. Tsuruta L, Lee HJ, Masuda ES, Koyano-Nakagawa N, Arai N, et al. (1995)
Cyclic AMP inhibits expression of the IL-2 gene through the nuclear factor of
activated T cells (NF-AT) site, and transfection of NF-AT cDNAs abrogates the
sensitivity of EL-4 cells to cyclic AMP. J Immunol 154: 5255–5264.
50. O’Neill EJ, Day MJ, Wraith DC (2006) IL-10 is essential for disease protection
following intranasal peptide administration in the C57BL/6 model of EAE.
J Neuroimmunol 178: 1–8.
51. Saraiva M, O’Garra A () The regulation of IL-10 production by immune cells.
Nat Rev Immunol 10: 170–181.
52. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, et al. (1999)
Tumor necrosis factor alpha decreases, and interleukin-10 increases, the
sensitivity of human monocytes to dexamethasone: potential regulation of the
glucocorticoid receptor. J Clin Endocrinol Metab 84: 2834–2839.
53. O’Flynn K, Krensky AM, Beverley PC, Burakoff SJ, Linch DC (1985)
Phytohaemagglutinin activation of T cells through the sheep red blood cell
receptor. Nature 313: 686–687.
54. Valentine MA, Tsoukas CD, Rhodes G, Vaughan JH, Carson DA (1985)
Phytohemagglutinin binds to the 20-kDa molecule of the T3 complex.
Eur J Immunol 15: 851–854.
55. Neves SR, Ram PT, Iyengar R (2002) G protein pathways. Science 296:
1636–1639.
56. Pavan B, Biondi C, Dalpiaz A (2009) Adenylyl cyclases as innovative therapeutic
goals. Drug Discov Today 14: 982–991.
57. Zippin JH, Farrell J, Huron D, Kamenetsky M, Hess KC, et al. (2004)
Bicarbonate-responsive ‘‘soluble’’ adenylyl cyclase defines a nuclear cAMP
microdomain. J Cell Biol 164: 527–534.
58. Reiffel JA (2000) Formulation substitution and other pharmacokinetic
variability: underappreciated variables affecting antiarrhythmic efficacy and
safety in clinical practice. Am J Cardiol 85: 46D–52D.
59. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, et al. (2003) The
sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic
acid: the SYDNEY trial. Diabetes Care 26: 770–776.
60. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, et al. (1999)
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-
lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III
Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.
Diabetes Care 22: 1296–1301.
61. Ziegler D, Reljanovic M, Mehnert H, Gries FA (1999) Alpha-lipoic acid in the
treatment of diabetic polyneuropathy in Germany: current evidence from
clinical trials. Exp Clin Endocrinol Diabetes 107: 421–430.
62. Jennings DL, Thompson ML (2009) Use of combination therapy with a beta-
blocker and milrinone in patients with advanced heart failure. Ann Pharmac-
other 43: 1872–1876.
63. Bryce PJ, Dascombe MJ, Hutchinson IV (1999) Immunomodulatory effects of
pharmacological elevation of cyclic AMP in T lymphocytes proceed via a protein
kinase A independent mechanism. Immunopharmacology 41: 139–146.
64. Furukawa Y, Matsumori A, Hirozane T, Matsui S, Sato Y, et al. (1996)
Immunomodulation by an adenylate cyclase activator, NKH477, in vivo and
vitro. Clin Immunol Immunopathol 79: 25–35.
65. Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka M, et al. (2002) Suppressive
effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells:
comparison with other types of cAMP-elevating agents. Neuropharmacology 42:
262–269.
66. McDonald W, Compston A, Edan G, Goodkin D, Hartung H-P, et al. (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the
international panel on the diagnosis of multiple sclerosis. Annals of Neurology
50: 121–127.
67. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, et al. (1983) New
diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann
Neurol 13: 227–231.
68. Kurtzke J (1983) Rating neurological impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology 33: 1444–1452.
cAMP/PKA Modulates LA Function
PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e13058